Back
Tarsus Pharmaceuticals Quote, Financials, Valuation and Earnings
Gold Set to Skyrocket as Fed Slashes Rates
Click here for the details on this incredible opportunity.
Buy
84
TARS
Tarsus Pharmaceuticals
Last Price:
44.62
Seasonality Move:
37.14%
7 Day Trial
ALL ACCESS PASS
$
7
AI DIVIDENDS: No. 1 Way to Collect Passive Income
Click here to get it for free.Tarsus Pharmaceuticals Price Quote
$44.62
+0.75 (+1.71%)
(Updated: October 30, 2024 at 6:10 PM ET)
Tarsus Pharmaceuticals Key Stats
Buy
84
Tarsus Pharmaceuticals (TARS)
is a Buy
Day range:
$38.90 - $46.71
52-week range:
$13.90 - $46.71
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
18.03
P/B ratio:
6.62%
Volume:
3M
Avg. volume:
672.9K
1-year change:
218.82%
Market cap:
$1.7B
Revenue:
$17.4M
EPS:
$-4.48
How Much Does Tarsus Pharmaceuticals Make?
-
How Much Are Tarsus Pharmaceuticals's Sales Annually?
TARS Revenues are $17.4M -
How Much Profit Does Tarsus Pharmaceuticals's Make A Year?
TARS net income is -$135.9M
Is Tarsus Pharmaceuticals Growing As A Company?
Data Unavailable
Tarsus Pharmaceuticals Stock Price Performance
-
Did Tarsus Pharmaceuticals Stock Go Up Last Month?
Tarsus Pharmaceuticals share price went up by 34.94% last month -
Did TARS's Share Price Rise Over The Last Year?
TARS share price rose by 218.82% over the past 1 year
What Is Tarsus Pharmaceuticals 52-Week High & Low?
-
What Is Tarsus Pharmaceuticals’s 52-Week High Share Price?
Tarsus Pharmaceuticals has traded as high as $46.71 over the past 52 weeks -
What Is Tarsus Pharmaceuticals’s 52-Week Low Share Price?
Tarsus Pharmaceuticals has traded as low as $13.90 over the past 52 weeks
Tarsus Pharmaceuticals Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Tarsus Pharmaceuticals?
-
How Much Debt Does Tarsus Pharmaceuticals Have?
Total long term debt quarterly is $71.6M -
How Much Cash Does Tarsus Pharmaceuticals Have?
Cash and short term investments quarterly total is $323.6M -
What Is Tarsus Pharmaceuticals’s Book Value Per Share?
Book value per share is 6.63
Is Tarsus Pharmaceuticals Cash Flow Positive?
-
What Is TARS Cash Flow From Operations?
Cash flow from operations (TTM) is -$123.9M -
What Is Tarsus Pharmaceuticals’s Cash Flow From Financing?
Cash flow from financing (TTM) is $275.7M -
What Is Tarsus Pharmaceuticals’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$77.5M
Tarsus Pharmaceuticals Return On Invested Capital
-
Is Management Doing A Good Job?
TARS return on invested capital is -59.01% -
What Is Tarsus Pharmaceuticals Return On Assets?
ROA measures how assets are converting to revenues and is -51.79% -
What Is TARS Return On Equity?
ROE is a measure of profitability and is -69.1%
Tarsus Pharmaceuticals Earnings Date & Stock Price
-
What Is Tarsus Pharmaceuticals's Stock Price Today?
A single share of TARS can be purchased today for 43.87 -
What Is Tarsus Pharmaceuticals’s Stock Symbol?
Tarsus Pharmaceuticals trades on the nasdaq under the ticker symbol: TARS -
When Is Tarsus Pharmaceuticals’s Next Earnings Date?
The next quarterly earnings date for Tarsus Pharmaceuticals is scheduled on November 8, 2024 -
When Is TARS's next ex-dividend date?
Tarsus Pharmaceuticals's next ex-dividend date is October 30, 2024 -
How To Buy Tarsus Pharmaceuticals Stock?
You can buy Tarsus Pharmaceuticals shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Tarsus Pharmaceuticals Competitors
-
Who Are Tarsus Pharmaceuticals's Competitors?
Below is a list of companies who compete with Tarsus Pharmaceuticals or are related in some way:
Tarsus Pharmaceuticals Dividend Yield
-
What Is TARS Dividend Yield?
Tarsus Pharmaceuticals’s dividend yield currently is 0% -
What Is Tarsus Pharmaceuticals’s Payout Ratio?
Tarsus Pharmaceuticals’s payout ratio is 0% -
When Did Tarsus Pharmaceuticals Last Pay A Dividend?
The latest dividend pay date is October 30, 2024 -
What Is Tarsus Pharmaceuticals’s Dividend Per Share?
Tarsus Pharmaceuticals pays a dividend of $0.00 per share
Tarsus Pharmaceuticals Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | -3.8% |
| Revenue: | 0% | 27.35% |
Analyst Recommendations
| Buy Recommendations: | 6 |
|---|---|
| Hold Recommendations: | 1 |
| Sell Recommendations: | 0 |
| Price Target: | 59.33 |
| Upside from Last Price: | 35.25% |